PharmAust Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PAA.AX research report →
Price Chart
About the company
Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment.
- CEO
- Michael Thurn
- IPO
- 2001
- Employees
- 52
- HQ
- Bentley, WA, AU
Get TickerSpark's AI analysis on PAA.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $111.93M
- P/E
- -1.61
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 9.47
- EV/EBITDA
- -2.29
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -254.33%
- ROIC
- -653.88%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-1,641+99.8%
- Op Income
- $-6,658,630
- Net Income
- $-9,032,356-45.4%
- EPS
- $-0.02-25.8%
- OCF Growth
- -230.4%
- FCF Growth
- -223.2%
- 52W High
- $0.54
- 52W Low
- $0.07
- 50D MA
- $0.18
- 200D MA
- $0.22
- Beta
- 1.55
- RSI (14)
- 40
- Avg Volume
- 898.65K
No earnings-call transcripts are available for PAA.AX yet.
- Free Float
- 74.0%
- Shares Outstanding
- 486.64M
- Float Shares
- 360.24M
Our PAA.AX coverage
Recent articles, reports, and earnings notes.
No research on PAA.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PAA.AX report →